01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
17:49 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies identified a benzopyran-based dual ESR1/ESR2 inhibitor and selective estrogen receptor down-regulator (SERD) that could help treat hormone therapy-resistant breast cancer. Chemical synthesis and testing in cell-based assays of...
15:14 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Roche scraps taselisib plans based on ASCO data

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However,...
12:28 , Jun 2, 2018 |  BC Extra  |  Clinical News

Roche scraps taselisib plans based on ASCO data

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However,...
17:45 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

G1 reports Phase Ib data for G1T38 in breast cancer

G1 Therapeutics Inc. (NASDAQ:GTHX) reported preliminary data from 24 estrogen receptor-positive, HER2-negative breast cancer patients in the Phase Ib portion of a Phase Ib/IIa trial showing that G1T38 plus Faslodex fulvestrant led to a partial...
18:22 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest agonizing ESR2 could help treat enteric nerve damage. In a mouse model of chemical-induced damage to the ileal myenteric plexus, a subcutaneous ESR2 agonist tool compound decreased the neuron-depleted area...
14:11 , May 18, 2018 |  BC Week In Review  |  Clinical News

Immunomedics reports Phase I/II metastatic breast cancer data for sacituzumab govitecan

Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic breast cancer in the Phase I/II IMMU-132-01 trial....
20:46 , May 17, 2018 |  BC Extra  |  Clinical News

Immunomedics reports Phase I/II metastatic breast cancer data

Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic breast cancer in the Phase I/II IMMU-132-01 trial....
16:05 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting PDGFCC alone or in combination with estrogen receptor antagonists could help treat breast cancer. In patients, high tumor levels of PDGFCC were associated with poor...
17:07 , Apr 6, 2018 |  BC Week In Review  |  Financial News

Arvinas raises $55M series C

Protein degradation company Arvinas LLC (New Haven, Conn.) raised $55 million in a series C round on April 4 led by new investor Nextech Invest. New investors Deerfield Management, Hillhouse Capital and Sirona Capital also...